Ducentis Bio
  • Home
  • Our Technology
  • Our Team
    • Management
    • Board Members
  • Investors
  • Contact Us

Management

Picture

Operational model

Ducentis operates as a virtual company, unencumbered by building leases or physical assets, and led by an experienced team with extensive drug discovery and development expertise. Our operational model ensures that investment is focused on securing a data package supporting IP protection, safety, tractable manufacturing options and strong evidence of efficacy in pre-clinical and clinical models.

Dr Philip Huxley

CEO and founder
Read chemistry at the University of Aberdeen and obtained a PhD in theoretical chemistry at the University of Sussex. Philip has a strong track record of innovation and delivery of drug development programmes with 30+ years of drug discovery and development experience at Novartis, British Biotech, Avidex, Galapagos and Bicycle Therapeutics. Philip has played pivotal roles in progressing novel, successful projects from conception to delivery of clinical candidates. He is a named inventor on numerous patents, including four phase II clinical candidates: Todestat, Rhudex, GLP0259 and BT5528.
Connect with Philip Huxley on LinkedIn

Dr Rebecca Ashfield

CSO and founder
Has a BA and DPhil from the University of Oxford, and 20+ years of pre-clinical and clinical experience developing biologic therapies targeting autoimmunity, infectious diseases and cancer. Following a career in academia Rebecca worked at Immunocore (formerly Avidex) developing immuno-oncology therapies and the Jenner Institute (University of Oxford) developing vaccines. In 2018 Rebecca authored a grant application which secured £65M funding for the Vaccines Manufacturing and Innovation Centre (VMIC) in Harwell Oxfordshire, and in 2020 was co-opted from Ducentis to help outsource manufacturing of the Oxford SARS-CoV-2 vaccine.
Connect with Rebecca Ashfield on LinkedIn

Ducentis

Our Technology  |  Management  |  Board Members

Connect

Contact Us

Legals

Disclaimer
​Ducentis BioTherapeutics Ltd is a company registered in England. 
Registered office address:
264 Banbury Road, Oxford, Oxfordshire, OX2 7DY
Company registration number: 9307415.
© Copyright Ducentis BioTherapeutics 2022   |   Website Design & Development by Creative Remedy
  • Home
  • Our Technology
  • Our Team
    • Management
    • Board Members
  • Investors
  • Contact Us